Diffuse Large B-cell Lymphoma

• CLINICAL_TRIALS trial_result · 2017-01-27
  Clinical Trial Update: Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) [Phase 2]

  A Phase 2 trial evaluating metformin in combination with standard induction therapy for diffuse large B-cell lymphoma was terminated; result…

• CLINICAL_TRIALS research · 2017-01-26
  Clinical Trial Update: Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma

  This is an update on a multicenter prospective registry study of diffuse large B-cell lymphoma; the current status of the study is unknown.

• CLINICAL_TRIALS research · 2017-01-16
  Clinical Trial Update: The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma [NA]

  This document notes a clinical trial studying pegylated liposomal doxorubicin in combination with epirubicin for diffuse large B-cell lympho…

• CLINICAL_TRIALS trial_result · 2017-01-11
  Clinical Trial Update: Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients [Phase 2]

  Phase 2 study evaluating the addition of bortezomib (VELCADE) to RCHOP for previously untreated Non-Germinal B-Cell-like Diffuse Large B-Cel…

• CLINICAL_TRIALS trial_result · 2016-12-22
  Clinical Trial Update: A Phase II Study of Doxycycline in Relapsed NHL [Phase 2]

  Phase II trial of doxycycline in relapsed non-Hodgkin lymphoma was terminated and results were posted in 2016.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2016-12-06
  Clinical Trial Update: PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma [Phase 1, Phase 2]

  Clinical trial update describing the evaluation of PCAR-119 Bridge Immunotherapy as a pre-transplant treatment for CD19-positive leukemias a…

• CLINICAL_TRIALS withdrawal · 2016-11-25
  Clinical Trial Update: Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]

  This clinical trial update states that the Phase 2 study of MDV9300 in relapsed or refractory diffuse large B-cell lymphoma has been withdra…

• CLINICAL_TRIALS withdrawal · 2016-11-02
  Clinical Trial Update: A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) [Phase 2]

  The NAVIGATE Phase 2 study evaluating navitoclax added to bendamustine and rituximab for relapsed diffuse large B-cell lymphoma has been wit…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma

  An observational study of Rituximab in combination with CHOP as first-line therapy for diffuse large B-cell lymphoma was terminated.

• CLINICAL_TRIALS trial_result · 2016-10-31
  Clinical Trial Update: Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]

  Phase 1/2 study evaluating vorinostat with rituximab and chemotherapy for newly diagnosed diffuse large B-cell lymphoma across stages II-IV.

• CLINICAL_TRIALS trial_result · 2016-10-27
  Clinical Trial Update: STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma [Phase 2]

  A Phase 2 clinical trial update on the STORM regimen (temsirolimus, rituximab, and DHAP) for relapsed or refractory diffuse large B-cell lym…

• CLINICAL_TRIALS trial_result · 2016-10-25
  Clinical Trial Update: CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]

  Clinical trial update on CD19-targeted CAR-T cell therapy being tested in relapsed/refractory leukemias and lymphomas (Phase 1 and Phase 2).

• CLINICAL_TRIALS withdrawal · 2016-10-14
  Clinical Trial Update: R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma [Phase 2]

  A phase 2 trial of R-CHOP-B (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Bevacizumab) for diffuse large B-cell ly…

• CLINICAL_TRIALS trial_result · 2016-10-13
  Clinical Trial Update: A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 2]

  A Phase 2 trial of Brentuximab Vedotin in relapsed or refractory non-Hodgkin lymphoma has completed and results have been posted. The study …

• CLINICAL_TRIALS research · 2016-10-12
  Clinical Trial Update: Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma [NA]

  This clinical trial evaluates whether liver SUVmax from 18F-FDG PET/CT can predict prognosis in patients with Diffuse large B-cell lymphoma.…

• CLINICAL_TRIALS research · 2016-10-10
  Clinical Trial Update: 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma [NA]

  An update on a study evaluating an 18F-FDG PET/CT-based prognostic model to predict outcomes in patients with diffuse large B-cell lymphoma.

• CLINICAL_TRIALS trial_result · 2016-10-05
  Clinical Trial Update: Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) [Phase 2]

  This is a Phase 2 safety evaluation of combining ibritumomab tiuxetan (Zevalin) with a fludarabine-based reduced-intensity conditioning regi…

• CLINICAL_TRIALS research · 2016-10-05
  Clinical Trial Update: Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma [NA]

  The update investigates the clinical and prognostic relevance of sarcopenia in patients over 70 with diffuse large B-cell lymphoma, highligh…

• CLINICAL_TRIALS withdrawal · 2016-09-15
  Clinical Trial Update: AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 1]

  Phase 1 trial of AZD2014 plus novel anti-cancer agents for relapsed or refractory diffuse large B-cell lymphoma has been withdrawn.

• CLINICAL_TRIALS research · 2016-09-07
  Clinical Trial Update: a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies [Phase 2]

  A Phase 2 clinical trial update evaluating sequential CAR-T cell therapy followed by hematopoietic stem cell transplantation for relapse/ref…

• CLINICAL_TRIALS trial_result · 2016-09-07
  Clinical Trial Update: the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) [Phase 1, Phase 2]

  The study evaluates sequential administration of CD19-targeted and CD20-targeted CAR-T cell therapy in patients with diffuse large B-cell ly…

• CLINICAL_TRIALS trial_result · 2016-08-29
  Clinical Trial Update: A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a [Phase 3]

  Phase 3 trial comparing subcutaneous versus intravenous Rituxan in CD20+ diffuse large B-cell lymphoma and CD20+ follicular non-Hodgkin's ly…

• CLINICAL_TRIALS withdrawal · 2016-08-11
  Clinical Trial Update: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A Phase 1/Phase 2 study of Rituximab, Romidepsin, and Lenalidomide for recurrent or refractory B-cell non-Hodgkin lymphoma has been withdraw…

• CLINICAL_TRIALS research · 2016-08-03
  Clinical Trial Update: NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy [Phase 2]

  This document provides a Phase 2 clinical trial update for NM-IL-12 (recombinant human interleukin-12) in relapsed/refractory diffuse large …

• CLINICAL_TRIALS trial_result · 2016-08-01
  Clinical Trial Update: Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]

  Clinical trial update for PCAR-019 evaluating efficacy and safety in CD19-positive relapsed or refractory leukemia and lymphoma across Phase…